On Monday, Shares of Sabre Corp (NASDAQ:SABR), remained flat and closed at $26.16 in the last trading session. SABR stock opened its last trade at $26.18 and after floating in a range of $26.05 to $26.37. The company’s Market capitalization is $7.27 Billion with the total Outstanding Shares of 278.07 million. During the 52-week trading session the minimum price at which share price traded, registered at $22.03 and reached to max level of $30.45. Sabre Corporation (SABR), the leading technology provider to the global travel industry and one of the world’s leading software companies, has opened up its inaugural Asia Pacific hackathon, 14 to 16 October, to also include virtual entries from the global developer community.
“We’ve received an overwhelming response to the declarement of our first ever Asia Pacific hackathon, with over 200 participants registered already from Singapore and the Asia Pacific region. We’ve decided to add the virtual entry component to meet demand from additional overseas developers seeking to take part but unable to join in person,” commented Roshan Mendis, senior vice president of Sabre Travel Network Asia Pacific.
Additional challenges have also been declared to run alongside the overall ‘Best New Technology Application’ category, which has a Grand Prize of US$10,000. These include ‘Best Use of Virtual Reality’, a ‘Chatbot Challenge,’ and travel merchandising challenges that showcase the New Sabre Red Workspace widgets, Sabre’s advanced platform for selling and booking travel which will launch in 2017.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), jumped 1.17% and closed at $13.80 in the last trading session. IRWD stock opened its last trade at $13.63 and after floating in a range of $13.32 to $13.96. The company’s Market capitalization is $1.94 Billion with the total Outstanding Shares of 129.78 million. During the 52-week trading session the minimum price at which share price traded, registered at $7.35 and reached to max level of $16.17. A new survey conducted among primary care physicians and rheumatologists found that despite their overall agreement that gout is a serious and chronic medical condition with potential long-term consequences, patients remain at risk. Of physicians surveyed, 89 percent agree that achieving serum uric acid (sUA) levels <6 mg/dL is imperative, yet only 51 percent report their patients with gout are reaching this target.
Further, nearly all (94 percent) of healthcare providers (HCPs) surveyed indicate that gout needs to be treated aggressively given long-term consequences, but express frustration (82 percent) when treatments fail to control sUA levels. A majority (89 percent) of physicians surveyed express a desire for additional treatment options for their patients.
“What I find most concerning about these findings is that we as physicians agree gout is not only a painful, often debilitating disease, but can have long-term consequences like permanent joint damage. Moreover, studies are showing a good deal of association between gout and comorbid conditions such as cardiovascular disease and kidney disease. Yet clinicians who treat patients with gout are only getting about half of those patients to their target sUA levels,” said Paul Doghramji, M.D., Family Physician, Collegeville Family Practice, Collegeville, PA. “I think there are two reasons why: we haven’t had enough treatment options to assist manage the disease and there are continued misconceptions about gout that contribute to ineffective disease administration.”